Literature DB >> 14052972

MODERN ASPECTS OF THE TREATMENT OF HEMOPHILIA. II.

I A MOCHTAR, J G KOPPE.   

Abstract

Ways of obtaining "two-donor" fibrinogen, as described in an earlier communication,(1) with an optimal and more constant amount of Factor VIII activity were investigated. Four modifications of the method as originally described by Nitschmann et al. are described. This freshly prepared modified "two-donor" fibrinogen was used in the treatment of severe or moderately severe hemorrhage in 20 hemophiliacs. Comparison of the results with those obtained by intermittent transfusions of fresh plasma or fresh blood indicated that the modified "two-donor" fibrinogen was definitely the preferable preparation.

Entities:  

Keywords:  BLOOD TRANSFUSION; FACTOR VIII; FIBRINOGEN; HEMOPHILIA

Mesh:

Substances:

Year:  1963        PMID: 14052972      PMCID: PMC1921852     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  4 in total

1.  [Plasma transfusions in hemophilia. VI. New directions for the treatment of hemorrhage in hemophilia].

Authors:  S VAN CREVELD; I A MOCHTAR
Journal:  Ned Tijdschr Geneeskd       Date:  1959-01-31

2.  Human antihaemophilic factor. The preparation in a hospital of a concentrate for clinical use.

Authors:  C A HOLMAN; P WOLF
Journal:  Lancet       Date:  1963-07-06       Impact factor: 79.321

3.  [The determination of Factor VIII].

Authors:  G J den OTTOLANDER; A BLEYENBERG
Journal:  Hemostase       Date:  1961

4.  Modern aspects of the treatment of hemophilia.

Authors:  I A MOCHTAR
Journal:  Can Med Assoc J       Date:  1962-11-10       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.